


3SBio Inc.

**UBS Global Generic and
Specialty Pharmaceuticals
Conference**

Dr. Jing Lou, Chief Executive Officer

May 8, 2007





Disclaimer



Statements in this presentation regarding certain anticipated business prospects resulting from the approval constitute “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon 3SBio management’s current expectations, and actual results could differ materially. Among the factors that could cause 3SBio’s actual results to differ from what the company currently anticipates may include competition from other domestic and foreign pharmaceutical companies; the expected market growth for pharmaceutical products in China; market acceptance of 3SBio products; expected hospital or patient demand for our products; 3SBio’s ability to expand its production, sales and distribution network and other aspects of its operations; its ability to effectively protect its intellectual property; changes in the healthcare industry in China, including changes in the healthcare policies and regulations of the PRC government and changes in the healthcare insurance sector in the PRC; and fluctuations in general economic and business conditions in China. For additional information on these and other factors that may affect the 3SBio’s financial results, please refer to the company’s filings with the Securities and Exchange Commission at www.sec.gov. 3SBio undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this presentation.



Agenda



Agenda

- **Company Overview**
- **Key Strengths**
- **Product & Operational Overview**
- **Development Pipeline**
- **Financial Overview**
- **Concluding Remarks**



3SBio Listed on NASDAQ



- NASDAQ IPO on February 7, 2007
- Ticker Symbol: “**SSRX**”
- 8.45 million ADR shares floated at US\$16 per share
- Raised approx. US\$108.0 million in net proceeds
- Investor information at: www.3SBio.com

Providing World Class Care for China's Future




3SBio Inc. is a leading, fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China


- Therapeutically focused in oncology and nephrology
- 6 marketed products and 6 pipeline products under development
 - EPIAO, our Flagship product, is the No.1 EPO product in Chinese market since 2002 (source: IMS Health)
 - TPIAO, the first protein-based TPO therapeutic product approved in Chinese market
 - Multiple late- stage development programs
- Compelling revenue and profit growth
 - 4 Year Net Revenue CAGR: 20.6%
 - YoY Net Income Growth of 116.3% for first quarter 2007
- Company Facts:
 - Founded in 1993
 - Headquarters & Manufacturing facilities: Shenyang
 - Sales Headquarters: Beijing
 - Employees: 346 (as of May 1, 2007)




Cherish Life



Care for Life



Create Life





Built on a Solid Operational Foundation



1

Leading Biotechnology Company in the Most Rapidly Growing Pharmaceutical Market

2

Nationwide Sales, Marketing, and Distribution Network

3

Diverse Portfolio of Marketed Products with Leading Market Share and Exclusivity in Key Market Segments

4

Deep Pipeline of Product Candidates and Proven Research and Development Capabilities

5

High-quality, Proprietary Manufacturing Processes With Significant Cost Advantages

6

Operational Efficiency and a Track Record of Growth and Profitability

7


Experienced and Market - Oriented Management Team

The Chinese Pharmaceutical Market is Growing at Record Levels

China is expected to be the World's fifth largest pharmaceutical market in five years



(Market Size in US\$ billion)



Source: IMS Health


...and 3SBio is well positioned to capitalize on opportunities in China's fast-growing pharmaceutical market



Established Nationwide Sales and Marketing Network



We currently distribute our products in 18 provinces and the key major cities throughout China



We plan to grow our sales and marketing infrastructure to meet China's rapidly growing demand for our products



Diverse Portfolio of Marketed Products

Our products target the growing oncology and nephrology end markets

PRODUCT NAME	INDICATION (S)	LAUNCH DATE
EPIAO® (rhEPO) (益比奥®)	Anemia associated with renal failure or chemotherapy, peri-operative blood cell mobilization	1998
TPIAO® (rhTPO) (特比澳®)	Thrombocytopenia	1Q2006
Baolijin® (G-CSF) (保力津®)	Neutropenia	Aug 2006 ¹
Tietai® (Iron Sucrose Supplement) (铁泰®)	Iron-deficiency associated with anemia	Jan 2007
Intefen® (Interferon Alpha-2a, IFN) (因特芬®)	Cancer, Viral infectious diseases	1995
Inleusin® (IL-2) (英路因®)	Renal cell carcinoma, Metastatic melanoma, Tuberculosis	1996

¹ Represents the date the product was in-licensed



EPIAO – Our Flagship Product

EPIAO (益比奥) is an injectible recombinant human erythropoietin (rhEPO) that stimulates the production of red blood cells in patients with anemia and reduces the need for blood transfusions


Key Facts

- Only EPO approved for three distinct medical indications
 - Anemia associated with chronic renal failure
 - Anemia associated with chemotherapy,
 - Red blood mobilization before, during, and after surgery
- Market leading EPO product in terms of both revenues and volume since 2002

益比奥®
EPIAO® (rHuEPO)
重组人红细胞生成素







- First quarter 2007 net revenue from EPIAO up 12.7% YoY to \$3.3 million
- Only EPO product in China that has been approved for use in chemotherapy induced anemic cancer patients
- Strong brand recognized for quality and reliability
- Competitive pricing – less than 1/3 of its imported comparables produced overseas
- 8 year of post-marketing experience and ~7mm vials sold
- Approval for licenses to produce pre-filled syringe EPO under EPIAO brand name granted by SFDA, announced in March 2007.





EPIAO – Maintaining Market Leadership

EPIAO (益比奥) is an injectible recombinant human erythropoietin (rhEPO) that stimulates the production of red blood cells in patients with anemia and reduces the need for blood transfusions


No. 1 EPO product market in both units sold and revenues since 2002



The Chinese Biopharmaceutical Market Underdeveloped



The Growth of the Market is among the Fastest



TPIAO – Recently Launched, 1st-to-Market TPO



TPIAO (特比澳) is an injectible recombinant human thrombopoietin (rhTPO) product that stimulates production of megakaryocytes to release mature platelets and raising the circulating platelet count

- 1st protein-based therapeutic approved and launched for the treatment of chemotherapy-induced thrombocytopenia, or platelet deficiency, in China
- Phase III results demonstrated higher platelet count in approx. 78% of cancer patients and 85% of ITP patients
- Launched in January 2006
- Marketing exclusivity period of 5 years through 2010
- Rapidly penetrating the market
 - 21.4% of total sales at end of 1Q07, up from 8.2% for 1Q06
- 2 patents issued in China covering composition of matter expiring in 2015 and method of manufacturing expiring in 2020



Complementary Portfolio of Recently In-Licensed Products



Tietai Iron Sucrose Supplement

铁泰

- Intravenous sucrose solution of a bioavailable form of iron
- Indicated for the treatment of iron deficiency in anemia patients with end-stage renal disease
- Considered to have a superior safety profile compared to other forms of iron supplements

Key Highlights

- In-licensed exclusive rights from Shenyang Borui Pharmaceutical Co. Ltd. for 5 years in May 2006
- Highly complementary to the marketing of EPIAO in anemia as these patients often require IV Iron Supplements that occurs from dialysis
- Launched in China in 2005
- 1.5% of overall sales in first quarter 2007




Baolijin (G-CSF)

保力津

- A recombinant human granulocyte colony stimulating factor
- Indicated for the treatment of neutropenia, a condition associated with chemotherapy and characterized by low levels of neutrophils, a type of white blood cell important for fighting infections

Key Highlights


- In-licensed exclusive rights from Chengdu Biological Institute for 5 years in Aug 2006
- Highly complementary to the marketing of EPIAO and TPIAO for the treatment of cancer patients receiving chemotherapy
- 2005 annual sales for G-CSF products in China were about RMB900mm (~US\$114mm)



Distributing our Products to Developing Countries all over the World



We currently export EPIAO, Interferon, Inleusin (Interleukin), and Tietai to a number of developing countries




- Domestic Market
- 3SBio Export Countries
- Target Export Countries in Registration
- New Export Licenses 2006

2006 GMP approval for:

- Sri Lanka (March)
- Trinidad & Tobago (July)
- Republic of Yemen (August)
- Guatemala (September)
- Colombia (November).

Growing Export Sales

- Approximately 5% of total revenue in 2006
- 17.8% YoY increase in export sales in FY06



We expect to grow export sales in the coming years



Proven Research and Development Capabilities

Proven Track Record of Product Development & Commercialization

- Market driven product development effort with the goal of addressing large markets with significant unmet medical needs in oncology and nephrology
- Successfully developed and commercialized four protein-based therapeutics in China to date
- Proven ability to identify and in-license complementary product opportunities, which our Sales force could effectively market and grow sales

Highly experienced R&D professionals

- Highly experienced research personnel and medical professionals, many with advanced degrees and overseas training, with extensive experience in the healthcare and biotech research fields

Productive working relationship with the SFDA

- Our productive working relationship with the SFDA is critical when seeking regulatory approvals for new therapeutics in China



High-Dose EPIAO and NuPIAO

High-Dose EPIAO is a 36,000/IU formulation of EPIAO


NuPIAO is the second-generation EPIAO that is designed to have a longer half-life

Key Highlights

- Designed for rapid restoration of hemoglobin to normal levels among cancer patients
- There currently is no dosage form of this kind in China
 - Comparable to standardized dose used globally for anemia
 - Allows for less frequent administration- more convenient for both patient and caregiver
 - Expected to be premium priced
- Plan to complete clinical trials in 2007 and launch in 2008

Key Highlights

- Comparable in structure to Amgen's Aranesp, which is currently the only second-generation EPO product approved by the U.S. Food and Drug Administration
- Preliminary testing of NuPIAO has demonstrated an enhanced half-life comparable to the half-life of darbepoietin alpha
- Extended half-life and increased biologic activity should allow for less frequent administration- more convenient for both patient and caregiver
- Preclinical testing is complete and awaiting SFDA go ahead
- Clinical trials expected to start in 1H08




TPIAO for the Treatment of ITP

ITP is characterized by an immune system malfunction that perceives the body's platelets as foreign and destroys them, potentially resulting in dangerously low platelet counts

Key Highlights

- **New approach to treat ITP by stimulating the TPO receptor, directly increasing platelet production to outpace platelet destruction by the immune system**
- **Multicenter, randomized, placebo-controlled Phase III study in 200 ITP patients**
- **The primary endpoint of this trial is the measurement of platelet counts during the 14 day treatment**
- **Expect to complete Phase III clinical trial by the end of 2007**



NuLeusin– Our 2nd Generation IL-2



NuLeusin, our second-generation IL-2, is a genetically modified form of IL-2 possessing the same properties as naturally occurring IL-2

Key Highlights

- The genetic modification enabled us to produce a high dosage form of IL-2 that has increased stability, superior efficacy, and enhanced tolerability
- Comparable to Chiron's Proleukin, which received U.S. FDA approval for treatment of metastatic renal cell carcinoma in 1992, and for treatment of metastatic melanoma in 1998
- In 2005, we completed an open-label, non-randomized Phase II trial of NuLeusin in 22 patients with metastatic renal cell carcinoma
 - The data demonstrated that NuLeusin effectively reduced the size of the tumors in these patients
 - No serious adverse events reported in this study
- We are currently conducting a multicenter, open-label registrational Phase III clinical study for NuLeusin for the treatment of metastatic melanoma and metastatic renal cell carcinoma
 - Expect to complete Phase III trial in late 2007



Exciting Early-stage Pipeline Candidates

HPV Vaccine

Key Highlights

- Eradication of HPV is a preventative measure against the development of cervical cancer
- In the majority of developing countries, cervical cancer remains the number one cause of cancer-related deaths among women
- The detection rate of HPV in cervical cancer is 98%
- At least 50% of sexually active people will get HPV at some time in their lives
- The annual increase of new Pap smear-positive cases in China is about 10 million
- Our HPV vaccine candidate targets VLPs of HPV-16 and HPV-18

Anti-TNF Humanized mAb

Key Highlights

- Anti-TNF humanized monoclonal antibody designed to bind and deactivate circulating TNF molecules
 - Similar in function to Enbrel, Remicade, and Humira
- We plan to develop our anti-TNF mAb candidate in collaboration with Eptomics, Inc.
 - US-based biotechnology company that is recognized for its proprietary high-affinity rabbit monoclonal antibody humanization technology

Manufacturing and Facilities Overview



- State-of-the-art facility covering 3,000 square meters including a 1,600 square meter clean room
- cGMP certified manufacturing facility and voluntary applications of European Pharmacopoeia standards
- Composed of three departments including mammalian cell genetic engineering, bacterial genetic engineering, and formulation divisions
- High-end name brand equipment including bioreactors, centrifuges, chromatography systems and lyophilizers
- Significant capacity to accommodate substantial growth from key products
- Received the government award for R&D and manufacturing capability
 - “Model Manufacturing Base” – awarded by the Ministry of Science and Technology of the People’s Republic of China










EPIAO EU 3rd Party Testing Result

- A reputable preclinical testing center in EU
- CA conform to EU standard
- Potency meet the requirement of EU
- Glycosylation profile done by HPAEC-PAD mapping proved superior structure



Operational Efficiency and a Track Record of Growth and Profitability





Multiple Value Driving Milestones on the Horizon




<u>Event</u>	<u>Expected Date</u>
● Continued report of revenues and profits	
● Complete Phase III trial for High Dose EPIAO	3Q07
● Complete Phase III trial for TPIAO for ITP	4Q07
● Complete Phase III trial for NuLeusin	4Q07
● Initiate clinical trial for NuPIAO	1H08
● Launch High Dose EPIAO	2H08
● Launch TPIAO for ITP	2H08
● Launch NuLeusin	2H08
● In-license/acquire complementary products/technologies	2007/2008




Focused Strategy to Drive Growth and Profitability





Appendix



1Q07 Financial Highlights – Continued Growth



HIGHLIGHTS				
(in millions)	For the three month period ended March 31, 2006	For the year month period ended March 31, 2007		YoY Increase/ (Decrease)
	<i>RMB (unaudited)</i>	<i>RMB (unaudited)</i>	<i>US\$ (unaudited)</i>	%
Net Revenues:	28.1	35.4	4.6	26.0%
Gross profit	25.4	32.4	4.2	27.6%
Total operating expenses	16.3	20.9	2.7	28.1%
Research & development	0.4	2.2	0.3	406.3%
Sales, marketing & distribution	12.6	15.6	2.0	23.7%
General & administrative	3.3	3.1	0.4	-5.2%
Operating income	9.1	11.6	1.5	26.9%
Net income	7.5	16.2	2.1	116.3%
Net income per ADS Basic and diluted (unaudited)	.52	0.87	0.11	-

Strong Performance from our Leading Products



NET REVENUES					
(in millions)	Three-month period ended				
	March 31, 2006	December 31, 2006	March 31, 2007	March 31, 2007	YoY Increase/ (Decrease)
	<i>(unaudited) RMB</i>	<i>(unaudited) RMB</i>	<i>(unaudited) RMB</i>	<i>(unaudited) US\$</i>	%
EPIAO	22.3	26.0	25.1	3.3	12.7%
TPIAO	2.3	5.9	7.6	1.0	227.4%
Intefen	1.6	1.5	1.0	0.1	(39.8%)
Inleusin	0.3	0.3	0.3	-	-
Export	1.4	1.2	0.7	0.1	(53.4%)
Others	0.2	0.3	0.7	0.1	342.9%
Totals	28.1	35.2	35.4	4.6	26.0%



Solid and Healthy Balance Sheet





BALANCE SHEET			
(in millions)	December 31, 2006 <i>(unaudited) RMB</i>	March 31, 2007 <i>(unaudited) RMB</i>	March 31, 2007 <i>(unaudited) US\$</i>
Cash	25.4	929.8	120.4
Current Assets	88.5	997.9	129.2
Total Assets	142.5	1,050.7	136.0
Current Liabilities	39.2	125.2	16.2
Bank debt	40.0	30.0	3.9
Total Liabilities	68.7	129.6	16.8
Minority Interests	0.5	0.5	0.1
Shareholders' Equity	73.3	920.6	119.2
Total Liability and shareholders' Equity	142.5	1,050.7	136.0

China's Pharmaceutical Industry Growth is outpacing China's GDP Growth




Increasing income and health awareness of the Chinese population have, and are expected to continue to, drive the growth of the pharmaceutical market




Source: OTC Pharmaceuticals in China: An Overview, ISI Emerging Markets 2005


Trends Contributing to the Rapid Growth of the Chinese Pharmaceutical Market




Source: Survey by National Bureau of Statistics in 2000 and 2005, and 2010E is according to the PRC National Population and Family Planning Commission statistics



Source: OTC Pharmaceuticals in China: An Overview, ISI Emerging Markets 2005




Source: China Statistical Yearbook 2005



Market Growth



Pharmaceutical Market in Hospitals (>=100 beds)



Experienced and Market-Oriented Management Team



Our management team has extensive experience in China's biopharmaceutical industry and a solid understanding of both Chinese and international industry best practices

Jing Lou, M.D., Ph.D.
CEO and Director

Has been with 3SBio since 1995, and built 3Sbio into the Chinese leading biopharmaceutical company. Has more than 10 years' pharmaceutical industry experiences. Post-doctoral training at NIH; and Ph.D. from Fordham Univ. in Molecular and Cellular Biology

Clara Mak, MBA,
CA, CPA
CFO

Joined 3SBio in 2006. Possesses more than 7 years of private equity experience in Asia and has extensive audit and financial advisory experiences with Arthur Andersen, Deloitte & Touche in Canada and Price Waterhouse in Hong Kong. CPA in US and CA in Canada. MBA from University of Toronto

Yingfei Wei, Ph.D.
CSO and VP of
Business Development

CSO since 2006. Responsible for 3SBio's Research and Development, partnership, and technology division. Former R&D research director of Bayer in San Francisco, and former senior research scientist at Human Genome Sciences. Post-doctoral fellow at Harvard and Ph.D. from University of California

Dongmei Su, MSc.
CTO



Joined in 1993. In Charge of the 3SBio's manufacturing, processing engineering. Co-inventor of several of 3SBio's patents. Masters in Microbiology and Pharmacology, and BSc in Biochemical Engineering from Jilin University

Ke Li, MSc., MBA
Regulatory

Joined in 1993. Responsible for all corporate and regulatory matters. MBA from Liaoning University, and BSc in Engineering from Jilin University




Company History





Organization Structure





3SBio Patents



Title	Application No.	Application Date	Status	Patent No.
Human thrombopoietin	95110172.2	4/14/1995	Issued	ZL 95110172.2
Process for preparing recombinant human thrombopoietin preparation	00109612.5	6/19/2000	Issued	ZL 00109612.5
Method for improving stability of polypeptide in body and its application	01128011.5	8/7/2001	Issued	ZL 01128011.5
Recombinant alpha interferon gelatin injection	02132574.X	7/11/2002	Issued	ZL 02132574.X
Stable erythropoietin of recombined human red blood cell	03100653.1	1/20/2003	Issued	ZL 03100653.1
Production of a interleukin mimetics	20610046222.2	3/31/2006	Filed	



Government Regulation Trends



- Increased government spending
- Price cuts will be less frequent in the future
- New SFDA to become more cautious on approval
- Anti-corruption will be more focused on the distribution channels
- New healthcare system
- Common Name System
- Pharmacy trusteeship
- Designated drug manufacturing



Overview of the Chinese Reimbursement System



- All employers in urban cities are required to enroll their employees in the basic medical insurance program and the insurance premiums are jointly contributed by the employers and employees*
- Drugs that are covered by the basic insurance program are limited to those listed in the Insurance Catalogue, including:
 - Pharmaceutical products listed in the 2005 version of the PRC Pharmacopoeia
 - Pharmaceutical products approved by the government to be in compliance with national standards, and
 - Imported pharmaceutical products approved by the government
- Insurance Catalogue consists of two parts, Part A and Part B:
 - Patients purchasing drugs included in Part A are entitled to reimbursement of the entire amount of purchase costs
 - Patients purchasing drugs included in Part B are required to pay a deductible and obtain reimbursement for the remainder of the purchase costs. The amount of deductible differs from region to region in China

* Pursuant to the Decision of the State Council on the Establishment of Basic Medical Insurance System for Urban Employees issued by the State Council on December 14, 1998



Price Control in Chinese Healthcare Industry



- Prices of pharmaceutical products are either determined by the government or by market conditions
- The government sets a price ceiling for the retail prices of products based on:
 - the average production cost of the pharmaceutical manufacturers
 - the market demand and supply of such products while allowing some room for adjustment from time to time
- Pharmaceutical products included in the Insurance Catalogue or those which tend to have a monopoly nature, are subject to overall price review to:
 - reduce the retail price of certain overpriced pharmaceutical products, or to
 - increase the retail price of certain underpriced pharmaceutical products with demand in clinical use but the manufacturers have little incentive to produce due to their low retail price levels
 - In particular, the retail price charged by hospitals at the county level or above may not exceed 115% of the procurement cost of the relevant pharmaceutical products or 125% for certain Chinese medicine products
- If a particular pharmaceutical manufacturer has an advantage over efficacy, safety, treatment cycle and treatment costs of its product, such pharmaceutical manufacturer may apply for an approval for exemption from price control, subject to a public hearing held by the government
- The State Development and Reform Commission issued the Notice to regulate the maximum retail price as well as the maximum post factory price of certain pharmaceutical products intended to treat vitamin or mineral deficient diseases

Overview of Chinese Administrative Protection Laws



- The 1999 Regulations provides a six to twelve year administrative protection period for different categories of new drugs
 - During the protection period of a new drug manufactured by a specific pharmaceutical company, other enterprises or individuals are prohibited from manufacturing a similar drug or expanding the label of any existing similar drug to include the same indication
- The 1999 Regulations were replaced by the 2002 Regulations, which was later revised in February 2005. However, any drug granted a protection period prior to September 2002 will still enjoy the protection period until its expiry
- The 2002 Regulations provide an administrative monitoring period of up to five years for new drugs approved to be manufactured, to continually monitor the safety of those new drugs
 - During the monitoring period of a new drug, the SFDA will not approve any other enterprises' application to manufacture or import a similar new drug
 - Only exception: SFDA will continue to handle any application if, prior to the commencement of the monitoring period, the SFDA has already approved the applicant's clinical trial for a similar new drug. If such application conforms to the relevant provisions, the SFDA may approve such applicant to manufacture or import the similar new drug during the remaining of the monitoring period



Clinical Trial Overview (China vs U.S.)

	U.S.	China
Characterization of Cell Bank	Karyology and Tumorigenicity NOT Required	Karyology and Tumorigenicity Required
Testing for IND/BLA	Not Required	1-3 batches for IND 3 batches for BLA
Pre-clinical Studies	6-9 months for Multi-Dose Toxicology Toxicokinetics Required	1-9 months for Multi-Dose Toxicology Toxicokinetics NOT Required Non-human primate are used in most of cases
Clinical trials	Phase I 20-80 subjects Phase II 100-300 subjects Phase III 1000-3000 subjects	Phase I 20-30 subjects Phase II 100 subjects Phase III 300 subjects